I am 42 years old and a HUGE skeptic about everything, so when I was introduced to InForce I did not believe a word. However, I was willing to try anything. I had been diagonosed with low levels of testoterone and I was completely lethargic. I hated waking up in the morning and found doing simple things very difficult to do. My Dr. prescribed Testosterone shots of which raised my levels but did not give me that much more energy as told. I decided to try inForce and to my delight I was very surprised. Within days I felt I had more energy than I have had in years. I felt like I was in my twenties again. It has been 3 months and I am off the shots and my levels are normal and I have a ton of energy.
I have suffered with severe sinusitis for almost 40 years( I am 72 now).I have had to take antibiotics very regularly,painkillers most of the time,daily nasal sprays and steam inhalations to try and clear the congestion.I have tried just about everything on the market , as this condition has coloured my life for a very long time.I have also suffered frequent headaches and a feeling of being unbalanced( because of congestion affecting my ears) from time to time.
I have had x-rays of my head and MRI scans–they told me that it was the shape of my face that was the problem and that there was nothing that could be done for me surgically.
Then along comes Coriolus and I decided to give it a go too!I have been taking Inforce for just over 3 months and in all that time I have not taken any antibiotics,painkillers,nasal sprays,inhalations.Now for me that is a miracle!It has not gone away totally but just being able to go without all of the medication is an amazing thing for me.
I function better on a daily basis.I have been taking 12 capsules a day for 14 weeks and now I am thinking of scaling the dosage down to see what the effect will be.Watch this space!!
Joan Ebsworth
Zheng-de Zhang1, Zhen-bin Qian2, Lan-feng Zhou2 and Bin Xu1 1 Shanghai Institute of Materia Medica, Academia Sinica 2 Department of Toxicology, Shanghai Institute of Labour Health and Occupational Diseases
Abstract
PSP is a new immunomodulating agent prepared and developed by Professor Qing-yao Yang. In the present work its influence on the behavior and growth of fetus in 1st and 2nd generation of rats was investigated.
For behavior study the squirrel wheel test, rotating cylinder test and passive avoidance test were performed, PSP was administered orally at 60, 600 and 6000mg/kg. The results showed that no marked difference in the change of behavior was found between the control and treatment groups. The brain weights of two-generation rats had no marked change either.
For teratogeny test 110 rats were involved PSP was administered orally at 60, 600 and 6000mg/kg in different groups for 10 days. The conditions of the maternal body, embryonic survival and the function and growth of the fetuses were examined. After statistical tests no marked difference was observed in the control and treatment groups.
The data observed showed that PSP has no noticeable toxicity on fetus growth and on the behavioral performance of 1st and 2nd generation rats.
Informatioin Office of the Research Institute of Fungi Shanghai Teachers University
PSP and PSK are the 2 products of Yun Zhi ratified by Chinese Ministry of Public Health and Japanese Ministry of Public Health respectively.
PSK was first manufactured by Kureha Chemical Industry Co. Ltd. The PS in PSK represents polysaccharide and K represents the first alphabet of the name of this Company. It was originally written as PS-K and was later changed to PSK. o; The commercial name of the product is Krestin.
PSP was prepared by Professor Qing-yao Yang. It is like PSK and is also a kind of compound polysaccharide. On the molecules of the polysaccharide, the small molecular protein (polypeptide) is connected. So it is called Yun Zhi Duo Tang Tai or Yun Zhi Tang Tai. The Tang Tai English names were originally glycopeptide, proteoglucan, glycosaminoglucan, etc. But the polysaccharide is all composed of N-acetyl-amino-hexose. But the polysaccharides of PSP and PSK are not composed of N-acetylamino-hexose. So it is not suitable to use the name. So the word “polysaccharopeptide” or “polysaccharide-peptide” is used and is abbreviated as PSP or Ps-p.
According to the different degrees of extraction, there are a series of PSP products. PSP directly extracted from the mycelia of Yun Zhi is called Yun Zhi Polysaccharide-peptide (Trade mark Qing Kang) and PSP polysacchardie-peptide (Landford). The former is sold on the market of Mainland China and the latter is according to the export specifications and is sold overseas. These 2 products are mainly used for tumorous patients.
The essence of the product is obtained by further isolation of the crude product. It is called Essence of Mushroom (Yun Zhi) (The sole distributor is Winsor Health Products Ltd., Hong Kong) used for healthy purposes.
Japan is quite specialized in the research of Yun Zhi. Besides PSK, Hirose, S. et al, (1970), Naruse S. and Takeda S. (in 1970) and Sugiura M. (in 1980) isolated two anticancerous components of the mycelia of Yun Zhi respectively. The former is called
ASTO and latter D–II. In addition, Ito H. et al (in 1974) extracted from the fermented mash of Yun Zhi an anti-tumor component which does not contain protein and it is called Coriolan. Its chemical components are glucans (by Hayashida S. et al, in 1992). But the above-mentioned three components still remain in the process of pharmacological research and was not used in clinical application.
Though PSP and PSK are all a kind of protein bound polysaccharide and are all extracted from the deep layer cultivated mycelia, yet they use the different strains, fermented medium and different extracted methods. Thus there is a certain difference between PSP and PSK. It is known that in the polysaccharide of PSP there is fucose, while there is no fucose in PSP, which contains arabinose and rhamnose; while there are no such ingredients in PSK. On the other hand, according to the pharmacological and clinical research, PSP has the definite effect of alleviating pain and increasing appetite, while there is no such report on PSK. Comparison of Two Characterisitics of PSP and PSK
Items compared
Similarities
Dissimilarities
Fungi
Yun Zhi Coriolus versicolor (Fr.) Quel
PSP: Cov-1 strain PSK: CM-101 strain
Drug produced
PSP: capsule PSK: loose package
Powder color
brown
PSP: brown PSK: dark brown
Raw materials
deep-layer cultivated mycelia (2N)
Fermentation technology
with glucose as the main carbon source (25oC, 3 days)
Liang-zhong Xu, Jun Han and Gang Chen Laboratory of Pathology, Cancer Institute, Shanghai Medical University
Abstract
The anticancer effects of PSP purified products, PSP-A, PSP-B, PSP-C and crude product PSP-Cr and KS-2 were compared on four human tumor cell lines in vitro. It was found that the inhibition rate of cell proliferation of PSP-A was higher than that of PSP-Cr, PSP-B and PSP-C (P<0.05). On SPC cells, the inhibition rate of PSP-A at a dosage of 1000ug/ml was 62.7%, being the highest as compared with those on the other three cell lines.
Jin-Xu Zhou, Xin-li Shen, Zu-ming Shen, Xiao-yu Li Department of Pharmacology I Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 200031
Abstract
Polysaccharide peptide of Coriolus versicolor (PSP) is a new anti-tumor and immunomodulating drug. In this paper PSP showed direct inhibition on the cell proliferation of sarcoma 180 in vitro and inhibitory effect on the growth of murine sarcoma 180 in vivo. Owing to its direct cytotoxic effect was not strong, but at lower concentrations (10-20ug/ml) of PSP promoted the proliferation of T and pre-T cells of mouse thymus, increased the thymus weight, provided more number of lymphocytes, prevented the involuation of thymus in tumor bearing mice and antagonized the anti-tumor action of PSP combined with antilymphocyte serum. It is suggested the principal mechanism of anti-tumor activity of PSP was T-cell mediated cytotoxicity.
It has been known that some polysaccharides and polysaccharide peptide isolated from various natural sources, especially isolated from Basiodiomycetes have certain anti-tumor activities. The polysaccharide contained a main chain of an alpha and beta (1-4) glucan and a tightly bound 15-38% polypeptides (PSP) isolated from Coriolus versicolor (Fr) Quel. (Cov-1) by Professor Qing-yao Yang also exhibited antitumor action against mouse sarcoma 180 in vitro and in vivo. Recent experiments suggest three possible mechanism by which these PSP might act: (1) Potentiating of T-cell mediated cytotoxicity which killed more number of target-tumor cells. (2) Definite concentration of PSP produced direct cytotoxic activity in vitro. (3) Induction of tumorcidal macrophages killed more cancer cells. In this paper the antitumor action of PSP and its possible mechanism are reported
W.C. Xue and T.F. Liu Cancer Hospital, Shanghai Medical University
There is no really effective treatment for moderate and advanced stages of esophageal carcinoma. Although surgery for the earlier cases has been able to give a 5 years survival rate of 28.7%, such operable cases are relatively few. By far the greater majority are already in stage III to IV when first seen in the clinic, and radiotherapy alone in these cases has given a 5 years survival rate of only 8-14%. In order to improve treatment results, a variety of chemotherapeutic agents have been used in combination surgery, but so far no really effective drug has been found.
The drug PSP (polysaccharide-peptide of Coriolus versicolor) has been discovered and produced by Professor Qing-yao Yang of. It is a new anti-cancer and immuno-regulatory drug, similar to PSK (Krestin) but the effective component has been found to be larger than PSK. Experimental data has proved these properties of PSP, and in vitro as well as in vivo studies have all proved that PSP is superior to PSK. Of course, as is the case with all new drugs, the ultimate proof of its value will have to be shown by clinical application.
The incidence of prostate cancer varies greatly throughout the world; it is highest in African-Americans and lowest in the Asian populations of China, India, and Japan. Geographical differences in both prevalence of latent prostate cancer and mortality have been postulated to be influenced by diverse tumor-promoting and protective factors, both environmental and dietary. Prostate cancer is a tumor with an extremely long latency; the pattern of prostate tumorigenesis, in terms of the display and sequence of appearance of particular molecular or biochemical features, or morphological changes, characterizing different stages of the carcinogenic process, is expected to be heterogeneous. Some insights into tumor heterogeneity and progression can be obtained from studies using cell lines, particularly those derived from different anatomical sites. The present study aims to investigate whether hormone-responsive LNCaP and androgen-refractory JCA-1, PC-3, and DU-145 prostate cancer cells are responsive to Yunzhi (YZ), a proprietary dietary supplement prepared from extracts of Trametes versicolor, also known as Coriolus versicolor (a mushroom consumed by Chinese for its purported health benefits), and to elucidate its mechanism of action. Ethanolic extracts (70%) of YZ significantly reduced LNCaP cell growth, down-regulated the levels of secreted PSA, but had less effects on the expression of intracellular PSA and did not affect levels of the androgen receptor. In androgen-unresponsive prostate cancer cells, YZ had a much less pronounced suppressive effect on proliferation of PC-3 and DU-145 cells, compared to LNCaP, and was inactive against JCA-1 cells. Western blot analyses show that the expression of Rb, a key regulatory protein in G1/S transition, and PCNA, integrally involved in mammalian cell DNA replication, were significantly reduced by treatment with YZ in PC-3 and DU-145 cells, respectively. In contradiction, none of these biochemical parameters were affected in JCA-1 cells under identical treatment conditions. Further analysis shows that YZ increased the levels of signal transducer and activator family of transcription factors STAT 1 and STAT 3 in JCA-1 and not LNCaP cells. The greater sensitivity of LNCaP cells to this polysaccharopeptide raises the possibility that YZ may be considered as an adjuvant therapy in the treatment of hormone responsive prostate cancer; additionally, it may have chemopreventive potential to restrict prostate tumorigenic progression from the hormone-dependent to the hormone-refractory state.
Department of Radiation Medicine (Radiobiology Program), Loma Linda University and Medical Center, Loma Linda, Calif. 92354, USA. xmao@dominion.llumc.edu
Long-term control of high-grade brain tumors is rarely achieved with current therapeutic regimens. The major goal of this study was to determine whether polysaccharopeptide (PSP), a crude polysaccharide peptide extract derived from Coriolus versicolor, a fungus, could enhance the effects of radiation against glioma cells in culture and in xenografted tumors in vivo. PSP significantly augmented radiation-induced damage to C6 rat glioma cells in vitro. Nude mice injected subcutaneously with the C6 cells were treated with PSP (injected intraperitoneally at 2 mg/injection) and radiation (2 Gy/fraction, 8 Gy in total) using three different time-dose protocols. Tumor volumes were consistently smaller in all treated groups compared to the non-treated tumor-bearing controls except in one group which received PSP prior to tumor implantation. The administration of radiation alone resulted in the slowest tumor progression, whereas PSP alone had no effect. Furthermore, PSP in combination with radiation treatment did not increase radiation efficacy. Natural killer cell, lymphocyte and granulocyte counts in blood and spleen were significantly higher in PSP-treated animals, demonstrating that PSP has protective effects on immunological function. Collectively, these results warrant further investigation to determine if PSP can be effectively utilized to upregulate immune responsiveness in case of neoplasia and other diseases in which immunosuppression is a prominent feature.
Clinical observation on alleviating chemotherapy side effects of psp in treating gastric carcinoma (in Chinese)